Business Context and Reporting Period
This filing is the Form 10-K of Nile Therapeutics, Inc., not Capricor Therapeutics, Inc. It covers the fiscal year ended December 31, 2012 and was filed June 21, 2013. Nile was a development-stage biopharmaceutical company focused on cardiovascular and renal diseases, principally heart failure.
- Cenderitide: Lead clinical-stage product candidate for post-acute heart failure. Its Phase 1 study was completed in 2011, but further development was on hold because the company lacked capital.
- CU-NP: Preclinical cardiovascular and renal candidate; all development was also on hold.
- The company had no approved products, no product sales and no product revenue. It had two full-time employees as of December 31, 2012.
Financial Performance and Position
| Metric | 2012 | 2011 |
|---|---|---|
| Total income | $195,500 | $1.35 million |
| Collaboration income | $195,500 | $1.35 million |
| Research and development expense | $1.02 million | $4.14 million |
| General and administrative expense | $1.61 million | $2.12 million |
| Operating loss | $2.44 million | $4.90 million |
| Net loss | $1.89 million | $4.88 million |
| Basic and diluted loss per share | $0.04 loss | $0.13 loss |
| Cash used in operating activities | $2.19 million | $4.65 million |
| Cash and cash equivalents at year-end | $46,716 | $1.04 million |
| Working capital | $(159,000) | $769,000 |
| Stockholders’ equity | $(167,313) | $830,723 |
The company recorded $545,876 of other income in 2012, primarily from a decrease in the fair value of the warrant liability. The warrant liability was $63,384 at year-end. Total liabilities were $394,367, including $330,983 of current liabilities. The filing does not present conventional operating margins because the company had no product revenue; operating expenses substantially exceeded collaboration income.
Since inception through December 31, 2012, Nile reported an accumulated deficit of $46.7 million and cumulative operating cash outflows of $34.9 million. Financing activities provided $1.19 million in 2012, principally from the April 2012 equity offering.
Material Changes Versus the Prior Comparable Period
- Net loss declined by approximately $3.0 million, from $4.88 million to $1.89 million, primarily because clinical development activity was wound down.
- R&D expense decreased approximately $3.1 million, reflecting the near cessation of cenderitide development during 2012.
- G&A expense declined approximately $0.5 million because of lower compensation, professional fees and public-company costs.
- Collaboration income fell approximately $1.16 million as Medtronic reimbursement income declined and the clinical trial funding agreement expired in February 2012.
- Cash declined approximately $992,000 during 2012, from $1.04 million to $46,716, while working capital moved from a $769,000 surplus to a $159,000 deficit.
- Shares outstanding increased from 39,712,231 to 43,062,231 following the April 2012 offering, which sold 3.35 million shares and warrants to purchase 2.51 million additional shares.
Guidance, Outlook, Risks and Unusual Items
- Management estimated that the next Phase 2 cenderitide trial would cost approximately $15 million to $20 million and take about 30 months. No additional development could begin without substantial financing or a strategic transaction.
- At December 31, 2012, cash resources were insufficient to support operations. Including proceeds from a March 2013 convertible-note financing, management expected funding to last only through the end of the second quarter of 2013.
- The auditors reported substantial doubt about the company’s ability to continue as a going concern. Management stated that failure to obtain additional capital could force a shutdown and wind-down of the company.
- On March 15, 2013, the company issued secured, non-interest-bearing convertible notes with $450,000 principal for $382,500 of proceeds. The notes mature March 15, 2014 and include change-of-control conversion or repayment provisions.
- Nile was not in compliance with several Mayo Foundation license provisions, including annual maintenance-fee payments and requirements to actively pursue development. Amounts owed to Mayo at year-end included $132,600 for the cenderitide license and $35,000 for the CU-NP license. Failure to renegotiate could result in loss of both product rights.
- Material risks included clinical failure, regulatory delay or rejection, product safety issues, dependence on third-party manufacturers and collaborators, intellectual-property challenges, inability to obtain financing, dilution from future securities issuances and loss of key personnel.
- The common stock traded on the OTC Pink tier after suspension from Nasdaq in 2011 and was characterized as a penny stock, creating substantial liquidity and trading-risk concerns.
- The filing reported no pending legal proceedings and no off-balance-sheet arrangements.
Most Important Facts to Verify
- Confirm that the intended issuer is Nile Therapeutics, Inc.; the request metadata identifies Capricor Therapeutics, Inc., which does not match the filing.
- Verify the company’s ability to continue as a going concern, including cash availability after the March 2013 financing and subsequent capital raises.
- Review the status of negotiations with Mayo and whether the cenderitide and CU-NP licenses remained in force.
- Assess the terms, security and change-of-control consequences of the March 2013 convertible notes.
- Confirm whether cenderitide or CU-NP development resumed and whether any strategic partnership or acquisition was completed.
- Reconcile outstanding shares, warrants and options, including the 10.8 million warrants outstanding at December 31, 2012 and potential dilution from the convertible notes.